23 institutions including Samsung Medical Center
Seoul, South Korea
NCT Number: NCT02899455
A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia
Looking for future studies?
Notify Me19 year–75 year
All sexes
Interventional
Phase 3
Seoul, South Korea
This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial to evaluate the efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: baseline and 8 weeks
Time frame: baseline and 8 weeks
Time frame: baseline and 4 weeks
Time frame: baseline, 4weeks and 8 weeks
Time frame: baseline and 4weeks
Time frame: baseline, 4weeks and 8 weeks
Time frame: baseline, 4weeks and 8 weeks
Time frame: baseline, 4weeks and 8 weeks
Time frame: baseline, 4weeks and 8 weeks
Hanmi Pharmaceutical Company Limited
Industry
Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01764178
Cardiovascular Diseases, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT06486532
Cardiovascular Diseases, Dyslipidemias
Saint Louis Park, Minnesota, United States
View Trial DetailsNCT04977583
Cardiovascular Disease, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06543706
Body Weight, Brain Diseases
Beijing, Beijing Municipality, China
View Trial Details